Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

m heart attacks annually in the U.S.(iii)

About prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome who are managed with PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first in class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

This press release contains certain f
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using ... cell therapy treatments for central nervous system diseases, announced ... the NASDAQ Capital Market under the symbol "CUR." The ... NYSE MKT until the market close on July 10, ... to commence on July 13, 2015. ...
(Date:6/29/2015)... ... June 29, 2015 , ... The StampedeCon ... and for the fourth year in a row, will bring top technology professionals to ... place at the intersection of data and technology. The event is proudly sponsored by ...
(Date:6/29/2015)... YORK , June 29, 2015   For the ... life sciences to assess their overall digital maturity called ... show that these companies are not maturing fast enough. ... healthcare industry in numerous ways overall and customers are ... in terms of digital customer engagement.  ...
(Date:6/26/2015)... MILFORD, Mass. , June 26, 2015 /PRNewswire/ ... in vitro diagnostics manufacturers, today announced that it ... (CRADA) with the National Cancer Institute (NCI), part ... reference materials and positive controls for cancer assays. ... to mix and accurately quantitate control DNA biosynthetics ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... engineers across Wisconsin are learning new ways to ... sugars, soybeans, solar collectors, corn stover, wind farms, ... , ,State businesses, architects, and builders are national ... save energy and money. , ,Wisconsin policymakers and ...
... after the launch of wireless Internet service in downtown Madison, ... service offered by area coffee shops. , ,Now, Mad ... 10-block radius of Madison's Capitol Square and at Dane ... of them. The broadband service will add indoor wireless access ...
Whitewater, Wis . - Sharon Ethanol , a subsidiary of <a...
Cached Biology Technology:Wisconsin can offer what a federal energy research lab needs 2Wisconsin can offer what a federal energy research lab needs 3Wisconsin can offer what a federal energy research lab needs 4
(Date:6/8/2015)... June 8, 2015  The Secure Identity ... selection of Troy Potter of L-3 ... SIBA is a non-profit association that was established ... education and implementation of solutions that protect and ... ...
(Date:6/4/2015)... 2015  Today, the co-chairs of the Blue Ribbon Study ... biocontainment labs and USA Today,s ... concerns over the findings of lax safety standards and called ... "The state ... said Joe Lieberman , former senator and co-chair of ...
(Date:6/1/2015)... 1, 2015 According to ... Market by Application (Government, Military & Defense, Healthcare, ... and Security), Technology (Face Recognition, Fingerprint Recognition, Iris ... Recognition, and Others), Function (Contact and Non-Contact) & ... Europe , APAC, Row) - Global ...
Breaking Biology News(10 mins):Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 2Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4
... In the largest clinical trial to date to examine ... carriers with diseases other than breast and ovarian cancer, ... against advanced pancreatic and prostate cancers. Results of the ... Medicine at the University of Pennsylvania and Sheba Medical ...
... Ocean frontier explorer and world-renowned filmmaker James Cameron has ... San Diego as the recipient of the 2013 Nierenberg ... deliver a presentation on his record-setting DEEPSEA CHALLENGE expedition ... on Friday, May 31, on the UC San Diego ...
... have developed guidelines being used by foresters and the ... when planting trees., Maps developed by Laura Gray, a ... projections of climatically suitable habitat for tree species based ... , The work, published recently in the journal ...
Cached Biology News:PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2James Cameron to be publicly honored with Scripps Nierenberg Prize 2James Cameron to be publicly honored with Scripps Nierenberg Prize 3James Cameron to be publicly honored with Scripps Nierenberg Prize 4